Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Bader

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Oncotarget|July 10, 2018
RIOK1 kinase activity is required for cell survival irrespective of <i>MTAP</i> statusAlexandra Hörmann, Barbara Hopfgartner, Thomas Köcher, et al.
Nature Chemical Biology|July 5, 2016
Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibitionAnja F Hohmann, Laetitia J Martin, Jessica L Minder, et al.
Oncogenesis|February 24, 2018
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotypeUlrich A Hirt, Irene C Waizenegger, Norbert Schweifer, et al.
Chemmedchem|January 17, 2023
Discovery of a Chemical Probe to Study Implications of BPTF Bromodomain Inhibition in Cellular and in vivo ExperimentsPaola Martinelli, Otmar Schaaf, Andreas Mantoulidis, et al.
Nature Communications|September 29, 2025
Frustration in the protein-protein interface plays a central role in the cooperativity of PROTAC ternary complexesNing Ma, Supriyo Bhattacharya, Sanychen Muk, et al.
Molecular Cancer Therapeutics|August 7, 2016
Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora KinasesPatrizia Sini, Ulrich Gürtler, Stephan K Zahn, et al.
Molecular Cancer Therapeutics|September 11, 2024
Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose SchedulesAndreas Gollner, Dorothea Rudolph, Ulrike Weyer-Czernilofsky, et al.
Elife|March 27, 2019
Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cellsSimone Lieb, Silvia Blaha-Ostermann, Elisabeth Kamper, et al.
Scientific Reports|August 14, 2019
SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell linesKatharina Ehrenhöfer-Wölfer, Teresa Puchner, Cornelia Schwarz, et al.
Journal of Medicinal Chemistry|February 12, 2019
Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding FunctionsJohannes Popow, Heribert Arnhof, Gerd Bader, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Oncotarget|July 10, 2018
RIOK1 kinase activity is required for cell survival irrespective of <i>MTAP</i> statusAlexandra Hörmann, Barbara Hopfgartner, Thomas Köcher, et al.
Nature Chemical Biology|July 5, 2016
Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibitionAnja F Hohmann, Laetitia J Martin, Jessica L Minder, et al.
Oncogenesis|February 24, 2018
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotypeUlrich A Hirt, Irene C Waizenegger, Norbert Schweifer, et al.
Chemmedchem|January 17, 2023
Discovery of a Chemical Probe to Study Implications of BPTF Bromodomain Inhibition in Cellular and in vivo ExperimentsPaola Martinelli, Otmar Schaaf, Andreas Mantoulidis, et al.
Nature Communications|September 29, 2025
Frustration in the protein-protein interface plays a central role in the cooperativity of PROTAC ternary complexesNing Ma, Supriyo Bhattacharya, Sanychen Muk, et al.
Molecular Cancer Therapeutics|August 7, 2016
Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora KinasesPatrizia Sini, Ulrich Gürtler, Stephan K Zahn, et al.
Molecular Cancer Therapeutics|September 11, 2024
Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose SchedulesAndreas Gollner, Dorothea Rudolph, Ulrike Weyer-Czernilofsky, et al.
Elife|March 27, 2019
Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cellsSimone Lieb, Silvia Blaha-Ostermann, Elisabeth Kamper, et al.
Scientific Reports|August 14, 2019
SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell linesKatharina Ehrenhöfer-Wölfer, Teresa Puchner, Cornelia Schwarz, et al.
Journal of Medicinal Chemistry|February 12, 2019
Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding FunctionsJohannes Popow, Heribert Arnhof, Gerd Bader, et al.
Pageof 4